Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review

Cancer Treatment Reviews

Volumn 53, Issue , 2017, Pages 25-37

  Kroeze, Stephanie G C ^a   Fritz, Corinna ^a   Hoyer, Morten ^b   Lo, Simon S ^c   Ricardi, Umberto ^d   Sahgal, Arjun ^e   Stahel, Rolf ^a   Stupp, Roger ^a   Guckenberger, Matthias ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Concurrent; Immunotherapy; Stereotactic radiotherapy; Targeted therapy; Toxicity

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CRIZOTINIB; DABRAFENIB; ERLOTINIB; GEFITINIB; IPILIMUMAB; LIVER ENZYME; NIVOLUMAB; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TRAMETINIB; TRASTUZUMAB; VEMURAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; NICOTINAMIDE;

ACNE; ADRENAL METASTASIS; ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ANOREXIA; BLEEDING; BONE METASTASIS; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN METASTASIS; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; COLORECTAL CANCER; CONFUSION; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHAGIA; DYSPHASIA; ENDOCRINE DISEASE; ESOPHAGITIS; ESOPHAGUS CANCER; FATIGUE; FEVER; FISTULA; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; GLIOMA; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEADACHE; HEART INFARCTION; HEMOLYSIS; HEPATITIS; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HYPERTENSION; HYPONATREMIA; HYPOXIA; INTESTINE PERFORATION; KIDNEY CARCINOMA; KIDNEY FAILURE; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER METASTASIS; LUNG CANCER; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MALNUTRITION; MEDIASTINUM METASTASIS; MELANOMA; MELANOMA METASTASIS; MEMORY; MOLECULARLY TARGETED THERAPY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NON SMALL CELL LUNG CANCER; PANCREAS CANCER; PANCREAS METASTASIS; PRURITUS; RADIATION NECROSIS; RADIATION PNEUMONIA; RASH; REVIEW; SEIZURE; SIDE EFFECT; SKIN DISEASE; SKIN FIBROSIS; SKIN INDURATION; SMALL INTESTINE OBSTRUCTION; SPINAL CORD METASTASIS; SPINE METASTASIS; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC RADIOSURGERY; STEREOTACTIC RADIOTHERAPY; STEREOTACTIC TREATMENT; STOMACH CANCER; STOMACH PERFORATION; STOMACH ULCER; STOMATITIS; SURGICAL INFECTION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOSIS; TUMOR BLEEDING; UPPER GASTROINTESTINAL BLEEDING; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT; XEROSTOMIA; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; IMMUNOTHERAPY; META ANALYSIS; NEOPLASMS; PROCEDURES; RADIOSURGERY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CETUXIMAB; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; RADIOSURGERY;

EID: 85007575567     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.11.013     Document Type: Review

References (62)

1. [1] Network NCC. Non-Small Cell Lung Cancer (Version 4.2016). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf.
2. [2] Tan, D.S., Yom, S.S., Tsao, M.S., Pass, H.I., Kelly, K., Peled, N., et al. The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016. J Thorac Oncol 11 (2016), 946–963.
3. [3] Potters, L., Kavanagh, B., Galvin, J.M., Hevezi, J.M., Janjan, N.A., Larson, D.A., et al. American society for therapeutic radiology and oncology (ASTRO) and American college of radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 76 (2010), 326–332.
4. [4] Hecht, M., Zimmer, L., Loquai, C., Weishaupt, C., Gutzmer, R., Schuster, B., et al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol 26 (2015), 1238–1244.
5. [5] Fuks, Z., Kolesnick, R., Engaging the vascular component of the tumor response. Cancer Cell 8 (2005), 89–91.
6. [6] Suit, H.D., Willers, H., Comment on “Tumor response to radiotherapy regulated by endothelial cell apoptosis” (I). Science, 302, 2003, 1894 author reply.
7. [7] Reynders, K., Illidge, T., Siva, S., Chang, J.Y., De Ruysscher, D., The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 41 (2015), 503–510.
8. [8] Popp, I., Grosu, A.L., Niedermann, G., Duda, D.G., Immune modulation by hypofractionated stereotactic radiation therapy: therapeutic implications. Radiother Oncol 120 (2016), 185–194.
9. [9] Filippi, A.R., Fava, P., Badellino, S., Astrua, C., Ricardi, U., Quaglino, P., Radiotherapy and immune checkpoints inhibitors for advanced melanoma. Radiother Oncol 120 (2016), 1–12.
10. [10] Aibe, N., Yamazaki, H., Nakamura, S., Tsubokura, T., Kobayashi, K., Kodani, N., et al. Outcome and toxicity of stereotactic body radiotherapy with helical tomotherapy for inoperable lung tumor: analysis of Grade 5 radiation pneumonitis. J Radiat Res 55 (2014), 575–582.
11. [11] Brown, J.M., Carlson, D.J., Brenner, D.J., The tumor radiobiology of SRS and SBRT: Are more than the 5 Rs involved?. Int J Radiat Oncol Biol Phys 88 (2014), 254–262.
12. [12] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62 (2009), 1006–1012.
13. [13] Cabrera, A.R., Cuneo, K.C., Desjardins, A., Sampson, J.H., McSherry, F., Herndon, J.E. 2nd, et al. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. Int J Radiat Oncol Biol Phys 86 (2013), 873–879.
14. [14] Gutin, P.H., Iwamoto, F.M., Beal, K., Mohile, N.A., Karimi, S., Hou, B.L., et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75 (2009), 156–163.
15. [15] Omuro, A., Beal, K., Gutin, P., Karimi, S., Correa, D.D., Kaley, T.J., et al. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clin Cancer Res 20 (2014), 5023–5031.
16. [16] Wang, Y., Wang, E., Pan, L., Dai, J., Zhang, N., Wang, X., et al. A new strategy of cyberknife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema. J Neurooncol 119 (2014), 369–376.
17. [17] Barney, B.M., Markovic, S.N., Laack, N.N., Miller, R.C., Sarkaria, J.N., Macdonald, O.K., et al. Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys 87 (2013), 73–80.
18. [18] Clark, G.M., McDonald, A.M., Nabors, L.B., Fathalla-Shaykh, H., Han, X., Willey, C.D., et al. Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience. Neurooncol Pract 1 (2014), 172–177.
19. [19] Conde-Moreno, A.J., Garcia-Gomez, R., Albert-Antequera, M., Almendros-Blanco, P., De Las, Penas.-Bataller R., Gonzalez-Vidal, V., et al. Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas. Rep Pract Oncol Radiother 20 (2015), 231–238.
20. [20] Cuneo, K.C., Vredenburgh, J.J., Sampson, J.H., Reardon, D.A., Desjardins, A., Peters, K.B., et al. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 82 (2012), 2018–2024.
21. [21] Hasan, S., Chen, E., Lanciano, R., Yang, J., Hanlon, A., Lamond, J., et al. Salvage fractionated stereotactic radiotherapy with or without chemotherapy and immunotherapy for recurrent glioblastoma multiforme: a single institution experience. Front Oncol, 5, 2015, 106.
22. [22] Minniti, G., Agolli, L., Falco, T., Scaringi, C., Lanzetta, G., Caporello, P., et al. Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas. J Neurooncol 122 (2015), 559–566.
23. [23] Yomo, S., Hayashi, M., Salvage stereotactic radiosurgery with adjuvant use of bevacizumab for heavily treated recurrent brain metastases: a preliminary report. J Neurooncol 127 (2016), 119–126.
24. [24] Cabrera, A.R., Cuneo, K.C., Vredenburgh, J.J., Sampson, J.H., Kirkpatrick, J.P., Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme. J Natl Compr Canc Netw 10 (2012), 695–699.
25. [25] Hapani, S., Chu, D., Wu, S., Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10 (2009), 559–568.
26. [26] Comet, B., Kramar, A., Faivre-Pierret, M., Dewas, S., Coche-Dequeant, B., Degardin, M., et al. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 84 (2012), 203–209.
27. [27] Lartigau, E.F., Tresch, E., Thariat, J., Graff, P., Coche-Dequeant, B., Benezery, K., et al. Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer. Radiother Oncol 109 (2013), 281–285.
28. [28] Vargo, J.A., Ferris, R.L., Ohr, J., Clump, D.A., Davis, K.S., Duvvuri, U., et al. A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 91 (2015), 480–488.
29. [29] Heron, D.E., Rwigema, J.C., Gibson, M.K., Burton, S.A., Quinn, A.E., Ferris, R.L., Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study. Am J Clin Oncol 34 (2011), 165–172.
30. [30] Quan, K., Xu, K.M., Zhang, Y., Clump, D.A., Flickinger, J.C., Lalonde, R., et al. Toxicities following stereotactic ablative radiotherapy treatment of locally-recurrent and previously irradiated head and neck squamous cell carcinoma. Semin Radiat Oncol 26 (2016), 112–119.
31. [31] Vargo, J.A., Heron, D.E., Ferris, R.L., Rwigema, J.C., Kalash, R., Wegner, R.E., et al. Examining tumor control and toxicity after stereotactic body radiotherapy in locally recurrent previously irradiated head and neck cancers: implications of treatment duration and tumor volume. Head Neck 36 (2014), 1349–1355.
32. [32] Carlson, J.A., Nooruddin, Z., Rusthoven, C., Elias, A., Borges, V.F., Diamond, J.R., et al. Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. Neuro Oncol 16 (2014), 1006–1009.
33. [33] Kiess, A.P., Wolchok, J.D., Barker, C.A., Postow, M.A., Tabar, V., Huse, J.T., et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92 (2015), 368–375.
34. [34] Mathew, M., Tam, M., Ott, P.A., Pavlick, A.C., Rush, S.C., Donahue, B.R., et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 23 (2013), 191–195.
35. [35] Patel, K.R., Shoukat, S., Oliver, D.E., Chowdhary, M., Rizzo, M., Lawson, D.H., et al. Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol, 2015.
36. [36] Qin, R., Olson, A., Singh, B., Thomas, S., Wolf, S., Bhavsar, N.A., et al. Safety and efficacy of radiation therapy in advanced melanoma patients treated with ipilimumab. Int J Radiat Oncol Biol Phys, 2016.
37. [37] Silk, A.W., Bassetti, M.F., West, B.T., Tsien, C.I., Lao, C.D., Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2 (2013), 899–906.
38. [38] Tazi, K., Hathaway, A., Chiuzan, C., Shirai, K., Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med 4 (2015), 1–6.
39. [39] Golden, E.B., Demaria, S., Schiff, P.B., Chachoua, A., Formenti, S.C., An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 1 (2013), 365–372.
40. [40] Hiniker, S.M., Chen, D.S., Reddy, S., Chang, D.T., Jones, J.C., Mollick, J.A., et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 5 (2012), 404–407.
41. [41] Alomari, A.K., Cohen, J., Vortmeyer, A.O., Chiang, A., Gettinger, S., Goldberg, S., et al. Possible interaction of anti-PD-1 therapy with the effects of radiosurgery on brain metastases. Cancer Immunol Res, 2016.
42. [42] Ahmed, K.A., Stallworth, D.G., Kim, Y., Johnstone, P.A., Harrison, L.B., Caudell, J.J., et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 27 (2016), 434–441.
43. [43] Ahluwalia, M.S., Chao, S.T., Parsons, M.W., Suh, J.H., Wang, D., Mikkelsen, T., et al. Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1–3 newly diagnosed brain metastases. J Neurooncol 124 (2015), 485–491.
44. [44] Staehler, M., Haseke, N., Nuhn, P., Tullmann, C., Karl, A., Siebels, M., et al. Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. BJU Int 108 (2011), 673–678.
45. [45] Brade, A.M., Ng, S., Brierley, J., Kim, J., Dinniwell, R., Ringash, J., et al. Phase 1 trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 94 (2016), 580–587.
46. [46] Straka, C., Kim, D.W., Timmerman, R.D., Pedrosa, I., Jacobs, C., Brugarolas, J., Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months. J Clin Oncol 31 (2013), e401–e403.
47. [47] Iyengar, P., Kavanagh, B.D., Wardak, Z., Smith, I., Ahn, C., Gerber, D.E., et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol 32 (2014), 3824–3830.
48. [48] Kim, H.J., Kim, W.S., Kwon, H., Cho, Y.H., Choi, C.M., Effects of an epithelial growth factor receptor-tyrosine kinase inhibitor add-on in stereotactic radiosurgery for brain metastases originating from non-small-cell lung cancer. J Korean Neurosurg Soc 58 (2015), 205–210.
49. [49] Schwer, A.L., Damek, D.M., Kavanagh, B.D., Gaspar, L.E., Lillehei, K., Stuhr, K., et al. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 70 (2008), 993–1001.
50. [50] Weickhardt, A.J., Scheier, B., Burke, J.M., Gan, G., Lu, X., Bunn, P.A. Jr, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 7 (2012), 1807–1814.
51. [51] Wang, Z., Zhu, X.X., Wu, X.H., Li, B., Shen, T.Z., Kong, Q.T., et al. Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer. Am J Clin Oncol 37 (2014), 148–153.
52. [52] Gan, G.N., Weickhardt, A.J., Scheier, B., Doebele, R.C., Gaspar, L.E., Kavanagh, B.D., et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys 88 (2014), 892–898.
53. [53] Wolf, A., Zia, S., Verma, R., Pavlick, A., Wilson, M., Golfinos, J.G., et al. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. J Neurooncol 127 (2016), 607–615.
54. [54] Ahmed, K.A., Freilich, J.M., Sloot, S., Figura, N., Gibney, G.T., Weber, J.S., et al. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol 122 (2015), 121–126.
55. [55] Gaudy-Marqueste, C., Carron, R., Delsanti, C., Loundou, A., Monestier, S., Archier, E., et al. On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. Ann Oncol 25 (2014), 2086–2091.
56. [56] Ly, D., Bagshaw, H.P., Anker, C.J., Tward, J.D., Grossmann, K.F., Jensen, R.L., et al. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg 123 (2015), 395–401.
57. [57] Narayana, A., Mathew, M., Tam, M., Kannan, R., Madden, K.M., Golfinos, J.G., et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113 (2013), 411–416.
58. [58] Patel, B.G., Ahmed, K.A., Johnstone, P.A., Yu, H.M., Etame, A.B., Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. Melanoma Res, 2016.
59. [59] Liebner, D.A., Walston, S.A., Cavaliere, R., Powers, C.J., Sauvageau, E., Lehman, N.L., et al. Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib. Melanoma Res 24 (2014), 172–176.
60. [60] Peuvrel, L., Ruellan, A.L., Thillays, F., Quereux, G., Brocard, A., Saint-Jean, M., et al. Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. Eur J Dermatol 23 (2013), 879–881.
61. [61] Stefan, D., Popotte, H., Stefan, A.R., Tesniere, A., Tomaszewski, A., Lesueur, P., et al. Vemurafenib and concomitant stereotactic radiation for the treatment of melanoma with spinal metastases: a case report. Rep Pract Oncol Radiother 21 (2016), 76–80.
62. [62] Tan, T.H., Chen, D., Soon, Y.Y., Tey, J.C., Prevalence and predictors of bias in the reporting of primary efficacy and toxicity endpoints in randomized clinical trials of radiation oncology. J Med Imaging Radiat Oncol, 2016.